Condition

High Risk Prostate Cancer

ClinicalTrials.gov condition label

Clinical trials14

Recruiting7

Common interventions25

Lead sponsors shown14

Clinical trials

14 shown

Radiation Therapy Approaches for People With Prostate CancerNCT07751159 · 2026-07-31

Androgen-responsive POSLUMA-guided Intra-prostatic BoostNCT07393867 · 2026-04-29

Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate CancerNCT07189598 · 2026-03-02

Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.NCT07208240 · 2025-08-12

PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR TrialNCT06949254 · 2025-04-04

Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PETNCT06758882 · 2024-11-25

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerNCT05406999 · 2020-02-01

ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)NCT07777263 · 2026-10-01

NOT_YET_RECRUITING

Novel Imaging in Staging of Primary Prostate CancerNCT03537391 · 2018-03-01

PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.NCT03340272 · 2017-02-21

Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort StudyNCT07608419 · 2016-01-01

ACTIVE_NOT_RECRUITING

Enzalutamide/Leuprolide +/- Abiraterone/Pred in ProstateNCT02268175 · 2014-10-01

Neoadjuvant BKM120 in High-risk Prostate CancerNCT01695473 · 2013-04-23

Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate CancerNCT02107287 · 2011-08-01

Common interventions

Abiraterone AcetateDRUG2 ApalutamideDRUG2 EnzalutamideDRUG2 99mTC-HMDP planar bone scintigraphy (BS)DIAGNOSTIC_TEST1 99mTc-HMDP single photon emission computer tomography/computer tomographyDIAGNOSTIC_TEST1 Adaptive Stereostatic Body RadioTherapy (SBRT) including both Whole Pelvic RadioTherapy (WPRT) and dose-escalation on the Dominant Intraprostatic Lesion (DIL)PROCEDURE1 ADTDRUG1 Androgen Deprivation Therapy (ADT) +/- bicalutamideDRUG1 Androgen receptor (AR) inhibitorDRUG1 BKM120DRUG1 conventional or a moderately hypofractionatedPROCEDURE1 DarotamideDRUG1 Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomographyDIAGNOSTIC_TEST1 IMRT TechniqueRADIATION1 Leuprolide AcetateDRUG1 PARP inhibitorDRUG1 Prednisolone tabletsDRUG1 PrednisoneDRUG1 PSMA PETDIAGNOSTIC_TEST1 PSMA PET/CTDIAGNOSTIC_TEST1 RezvilutamideDRUG1 Robot-assisted radical prostatectomyPROCEDURE1 SBRTRADIATION1 Standard of Care HDR BrachytherapyRADIATION1 Stereotactic Body Radiation Therapy (SBRT) +/- focal microboostRADIATION1

Leading sponsors

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia1 Center Eugene Marquis1 Dana-Farber Cancer Institute1 Dr. Tamim Niazi1 General University Hospital, Prague1 Istituto Clinico Humanitas1 Marco Oderda1 Martin T. King, MD, PhD1 Memorial Sloan Kettering Cancer Center1 Rabin Medical Center1 Sergio Faria1 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 Turku University Hospital1 Won Kim1

Trial status mix

RECRUITING7

COMPLETED3

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

TERMINATED1

UNKNOWN1

Phase mix

PHASE27

NA3

PHASE11

PHASE31

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.